0000950170-24-025906.txt : 20240305 0000950170-24-025906.hdr.sgml : 20240305 20240305161022 ACCESSION NUMBER: 0000950170-24-025906 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240301 FILED AS OF DATE: 20240305 DATE AS OF CHANGE: 20240305 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BASTA JAMES CENTRAL INDEX KEY: 0001792726 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37766 FILM NUMBER: 24720420 MAIL ADDRESS: STREET 1: C/O KURA ONCOLOGY, INC. STREET 2: 3033 SCIENCE PARK RD, SUITE 220 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Intellia Therapeutics, Inc. CENTRAL INDEX KEY: 0001652130 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 364785571 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 40 ERIE STREET STREET 2: SUITE 130 CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-285-6200 MAIL ADDRESS: STREET 1: 40 ERIE STREET STREET 2: SUITE 130 CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 ownership.xml 4 X0508 4 2024-03-01 0001652130 Intellia Therapeutics, Inc. NTLA 0001792726 BASTA JAMES C/O INTELLIA THERAPEUTICS, INC. 40 ERIE STREET; SUITE 130 CAMBRIDGE MA 02139 false true false false EVP, General Counsel false Common Stock 2024-03-01 4 A false 32394 0 A 83868 D Common Stock 2024-03-04 4 S false 2297 32.99 D 81571 D Stock Option (right to buy) 32.66 2024-03-01 4 A false 46752 0 A 2034-02-28 Common Stock 46752 46752 D Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on March 1, 2024, and does not represent a volitional trade by the Reporting Person. This option was granted on March 1, 2024 with respect to shares of Common Stock, with 33% vesting on January 1, 2025 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter. James Basta 2024-03-05